Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8

Journal of Immunology

Volumn 191, Issue 3, 2013, Pages 1276-1286

  Ireland, Robin ^a   Wang, Rong ^a   Alinger, Joshua B ^a   Small, Pamela ^b   Bosio, Catharine M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 12P40; LIPID; TRANSCRIPTION FACTOR RELA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CONTROLLED STUDY; DENDRITIC CELL; FRANCISELLA TULARENSIS; HOST; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; DENDRITIC CELLS; FRANCISELLA TULARENSIS; I-KAPPA B PROTEINS; IMMUNE EVASION; IMMUNITY, INNATE; INFLAMMATION; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTORS; INTERLEUKIN-12 SUBUNIT P40; LIPIDS; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; TRANSCRIPTION FACTOR RELA; TULAREMIA;

EID: 84880662681     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300867     Document Type: Article

References (55)

1. Oyston, P. C., A. Sjostedt, and R. W. Titball. 2004. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2: 967-978.
2. Saslaw, S., H. T. Eigelsbach, J. A. Prior, H. E. Wilson, and S. Carhart. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. 107: 702-714.
3. Wayne Conlan, J., H. Shen, R. Kuolee, X. Zhao, and W. Chen. 2005. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell-And interferon gamma-dependent mechanism. Vaccine 23: 2477-2485.
4. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, et al; Working Group on Civilian Biodefense. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285: 2763-2773.
5. Eigelsbach, H. T., and C. M. Downs. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J. Immunol. 87: 415-425.
6. Risi, G. F., and D. J. Pombo. 1995. Relapse of tularemia after aminoglycoside therapy: case report and discussion of therapeutic options. Clin. Infect. Dis. 20: 174-175.
7. Bauler, T. J., J. C. Chase, and C. M. Bosio. 2011. IFN-b mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis. J. Immunol. 187: 1845-1855.
8. Bosio, C. M., H. Bielefeldt-Ohmann, and J. T. Belisle. 2007. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J. Immunol. 178: 4538-4547.
9. Butchar, J. P., T. J. Cremer, C. D. Clay, M. A. Gavrilin, M. D. Wewers, C. B. Marsh, L. S. Schlesinger, and S. Tridandapani. 2008. Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversion. PLoS ONE 3: e2924.
10. Chase, J. C., J. Celli, and C. M. Bosio. 2009. Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect. Immun. 77: 180-195.
11. Chase, J. C., and C. M. Bosio. 2010. The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect. Immun. 78: 154-167.
12. Elkins, K. L., T. R. Rhinehart-Jones, S. J. Culkin, D. Yee, and R. K. Winegar. 1996. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect. Immun. 64: 3288-3293.
13. Ireland, R., N. Olivares-Zavaleta, J. M. Warawa, F. C. Gherardini, C. Jarrett, B. J. Hinnebusch, J. T. Belisle, J. Fairman, and C. M. Bosio. 2010. Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog. 6: e1000921.
14. Sutherland, M. D., A. W. Goodyear, R. M. Troyer, J. C. Chandler, S. W. Dow, and J. T. Belisle. 2012. Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia. Vaccine 30: 4977-4982.
15. Huntley, J. F., G. T. Robertson, and M. V. Norgard. 2010. Method for the isolation of Francisella tularensis outer membranes. J. Vis. Exp. 40: 2044.
16. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226: 497-509.
17. Beatty, W. L., E. R. Rhoades, H. J. Ullrich, D. Chatterjee, J. E. Heuser, and D. G. Russell. 2000. Trafficking and release of mycobacterial lipids from infected macrophages. Traffic 1: 235-247.
18. Dunnick, J. K., and W. M. O'Leary. 1970. Correlation of bacteria lipid composition with antibiotic resistance. J. Bacteriol. 101: 892-900.
19. Liu, X., and R. Curtiss, III. 2012. Thermorecovery of cyanobacterial fatty acids at elevated temperatures. J. Biotechnol. 161: 445-449.
20. Bosio, C. M., and S. W. Dow. 2005. Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J. Immunol. 175: 6792-6801.
21. Semnani, R. T., P. G. Venugopal, C. A. Leifer, S. Mostböck, H. Sabzevari, and T. B. Nutman. 2008. Inhibition of TLR3 and TLR4 function and expression in human dendritic cells by helminth parasites. Blood 112: 1290-1298.
22. la Sala, A., J. He, L. Laricchia-Robbio, S. Gorini, A. Iwasaki, M. Braun, G. S. Yap, A. Sher, K. Ozato, and B. Kelsall. 2009. Cholera toxin inhibits IL-12 production and CD8alpha+ dendritic cell differentiation by cAMP-mediated inhibition of IRF8 function. J. Exp. Med. 206: 1227-1235.
23. Bublitz, D. C., C. E. Noah, J. L. Benach, and M. B. Furie. 2010. Francisella tularensis suppresses the proinflammatory response of endothelial cells via the endothelial protein C receptor. J. Immunol. 185: 1124-1131.
24. Cremer, T. J., D. H. Ravneberg, C. D. Clay, M. G. Piper-Hunter, C. B. Marsh, T. S. Elton, J. S. Gunn, A. Amer, T. D. Kanneganti, L. S. Schlesinger, et al. 2009. MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response. PLoS ONE 4: e8508.
25. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
26. Bohuslav, J., L. F. Chen, H. Kwon, Y. Mu, and W. C. Greene. 2004. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J. Biol. Chem. 279: 26115-26125.
27. Wong, B. C., Xh. Jiang, X. M. Fan, M. C. Lin, S. H. Jiang, S. K. Lam, and H. F. Kung. 2003. Suppression of RelA/p65 nuclear translocation independent of IkappaB-Alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 22: 1189-1197.
28. Taki, S., T. Sato, K. Ogasawara, T. Fukuda, M. Sato, S. Hida, G. Suzuki, M. Mitsuyama, E. H. Shin, S. Kojima, et al. 1997. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6: 673-679.
29. Goodridge, H. S., W. Harnett, F. Y. Liew, and M. M. Harnett. 2003. Differential regulation of interleukin-12 p40 and p35 induction via Erk mitogen-Activated protein kinase-dependent and -independent mechanisms and the implications for bioactive IL-12 and IL-23 responses. Immunology 109: 415-425.
30. Maruyama, S., K. Sumita, H. Shen, M. Kanoh, X. Xu, M. Sato, M. Matsumoto, H. Shinomiya, and Y. Asano. 2003. Identification of IFN regulatory factor-1 binding site in IL-12 p40 gene promoter. J. Immunol. 170: 997-1001.
31. Kamijo, R., H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, D. Shapiro, J. Le, S. I. Koh, T. Kimura, S. J. Green, et al. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263: 1612-1615.
32. Ma, X., M. Neurath, G. Gri, and G. Trinchieri. 1997. Identification and characterization of a novel Ets-2-related nuclear complex implicated in the activation of the human interleukin-12 p40 gene promoter. J. Biol. Chem. 272: 10389-10395.
33. Masumi, A., S. Tamaoki, I. M. Wang, K. Ozato, and K. Komuro. 2002. IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages. FEBS Lett. 531: 348-353.
34. Parsa, K. V., L. P. Ganesan, M. V. Rajaram, M. A. Gavrilin, A. Balagopal, N. P. Mohapatra, M. D.Wewers, L. S. Schlesinger, J. S. Gunn, and S. Tridandapani. 2006. Macrophage pro-inflammatory response to Francisella novicida infection is regulated by SHIP. PLoS Pathog. 2: e71.
35. Crane, D. D., D. P. Scott, and C. M. Bosio. 2012. Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS ONE 7: e33349.
36. Bar-Haim, E., O. Gat, G. Markel, H. Cohen, A. Shafferman, and B. Velan. 2008. Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection. PLoS Pathog. 4: e1000211.
37. Tigertt, W. D. 1962. Soviet viable Pasteurella tularensis vaccines. A review of selected articles. Bacteriol. Rev. 26: 354-373.
38. Fortier, A. H., M. V. Slayter, R. Ziemba, M. S. Meltzer, and C. A. Nacy. 1991. Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect. Immun. 59: 2922-2928.
39. Apicella, M. A., D. M. Post, A. C. Fowler, B. D. Jones, J. A. Rasmussen, J. R. Hunt, S. Imagawa, B. Choudhury, T. J. Inzana, T. M. Maier, et al. 2010. Identification, characterization and immunogenicity of an O-Antigen capsular polysaccharide of Francisella tularensis. PLoS ONE 5: e11060.
40. Hood, A. M. 1977. Virulence factors of Francisella tularensis. J. Hyg. (Lond.) 79: 47-60.
41. Wang, X., A. A. Ribeiro, Z. Guan, S. C. McGrath, R. J. Cotter, and C. R. Raetz. 2006. Structure and biosynthesis of free lipid A molecules that replace lipopolysaccharide in Francisella tularensis subsp. novicida. Biochemistry 45: 14427-14440.
42. Maeshima, N., and R. C. Fernandez. 2013. Recognition of lipid Avariants by the TLR4-MD-2 receptor complex. Front. Cell. Infect. Microbiol. 3: 3.
43. Beasley, A. S., R. J. Cotter, S. N. Vogel, T. J. Inzana, A. A. Qureshi, and N. Qureshi. 2012. Avariety of novel lipid A structures obtained from Francisella tularensis live vaccine strain. Innate Immun. 18: 268-278.
44. Schilling, B., M. K. McLendon, N. J. Phillips, M. A. Apicella, and B. W. Gibson. 2007. Characterization of lipid A acylation patterns in Francisella tularensis, Francisella novicida, and Francisella philomiragia using multiple-stage mass spectrometry and matrix-Assisted laser desorption/ionization on an intermediate vacuum source linear ion trap. Anal. Chem. 79: 1034-1042.
45. Melillo, A. A., C. S. Bakshi, and J. A. Melendez. 2010. Francisella tularensis antioxidants harness reactive oxygen species to restrict macrophage signaling and cytokine production. J. Biol. Chem. 285: 27553-27560.
46. Naumann, M., and C. Scheidereit. 1994. Activation of NF-kappa B in vivo is regulated by multiple phosphorylations. EMBO J. 13: 4597-4607.
47. Perkins, N. D. 2006. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25: 6717-6730.
48. Tamura, T., H. Yanai, D. Savitsky, and T. Taniguchi. 2008. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26: 535-584.
49. Sakaguchi, S., H. Negishi, M. Asagiri, C. Nakajima, T. Mizutani, A. Takaoka, K. Honda, and T. Taniguchi. 2003. Essential role of IRF-3 in lipopolysaccharideinduced interferon-beta gene expression and endotoxin shock. Biochem. Biophys. Res. Commun. 306: 860-866.
50. Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, M. Katsuki, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-Alpha/beta gene induction. Immunity 13: 539-548.
51. Henry, T., and D. M. Monack. 2007. Activation of the inflammasome upon Francisella tularensis infection: interplay of innate immune pathways and virulence factors. Cell. Microbiol. 9: 2543-2551.
52. Tamura, T., M. Ishihara, M. S. Lamphier, N. Tanaka, I. Oishi, S. Aizawa, T. Matsuyama, T.W. Mak, S. Taki, and T. Taniguchi. 1997. DNA damage-induced apoptosis and Ice gene induction inmitogenically activated T lymphocytes require IRF-1. Leukemia 11(Suppl 3): 439-440.
53. Lin, R., and J. Hiscott. 1999. A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity. Mol. Cell. Biochem. 191: 169-180.
54. Harada, H., T. Fujita, M. Miyamoto, Y. Kimura, M. Maruyama, A. Furia, T. Miyata, and T. Taniguchi. 1989. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFNinducible genes. Cell 58: 729-739.
55. Pion, E., V. Narayan, M. Eckert, and K. L. Ball. 2009. Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation. Cell. Signal. 21: 1479-1487.